New hope for kids with Drug-Resistant TB: bedaquiline studied in children

NCT ID NCT02906007

Completed Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looked at how safe and tolerable the drug bedaquiline is for children and teens with rifampin-resistant tuberculosis, including those also living with HIV. Fifty-four participants received bedaquiline along with their regular TB treatment for 24 weeks. Researchers measured side effects, heart safety, and how the drug moved through the body to find the right dose for young patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bedaquiline
What this could lead to: If successful, this study could help establish safe and effective dosing of bedaquiline for children with drug-resistant tuberculosis, improving treatment options for this vulnerable group.
What could go wrong: This was a small, early-phase study (54 participants) focused on safety and drug levels, not on cure rates. Side effects like heart rhythm changes and severe adverse events were monitored, and results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease rifampicin-resistant tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV TUBERCULOSIS

Contacts and locations

Locations

Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS

Cape Town, Western Cape, 7505, South Africa
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS

Port-au-Prince, HT-6110, Haiti
PHRU Matlosana CRS

Klerksdorp, North West, 2574, South Africa
Sizwe CRS

Johannesburg, Gauteng, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.